Zhongtao Wang1, Yongjun Wang2, Xinmei Zhang1, Tingting Zhang1. 1. Division of Pediatric Respiratory Medicine, Gansu Provincial Maternity and Child-Care Hospital, NO.143, Qilihe North Street, Qilihe District, Lanzhou City, Gansu Province, China. 2. Division of Pediatric Respiratory Medicine, Gansu Provincial Maternity and Child-Care Hospital, NO.143, Qilihe North Street, Qilihe District, Lanzhou City, Gansu Province, China. Electronic address: 2216128485@qq.com.
Abstract
BACKGROUND: Numerous studies have explored the association between pretreatment prognostic nutritional index (PNI) and prognosis in lung cancer (LC), but the results are still inconclusive. We systematically evaluated the prognostic value of pretreatment PNI in LC patients by conducting a meta-analysis. METHODS: A comprehensive literature search was performed by retrieving PubMed, EMBASE, and Web of Science, Wan Fang and CNKI databases. We used hazard ratios (HRs) and their 95% confidence intervals (CIs) to assess the associations of PNI with overall survival (OS), disease-free survival/recurrence-free survival (DFS/RFS) and progression-free survival (PFS) in LC patients. RESULTS: A total of 21 studies were enrolled into this meta-analysis, with 17 about no-small cell lung cancer (NSCLC) and 4 about on small-cell lung cancer (SCLC). The results indicated that NSCLC patients with low PNI had shorter OS (HR: 1.59, 95% CI: 1.28-1.96, P = 0.001), DFS/RFS (HR = 1.74, 95% CI = 1.08-2.80, P = 0.017), and PFS (HR = 1.52, 95% CI = 1.26-1.83, P = 0.002) than patients with high PNI. The robustness of these pooled results were verified by our stratified analysis and sensitivity analysis. Besides, a pooled analysis of 4 studies about SCLC suggested that low PNI was closely associated with worse OS in SCLC patients as well. CONCLUSION: Low PNI predicts poor survival in LC patients.
BACKGROUND: Numerous studies have explored the association between pretreatment prognostic nutritional index (PNI) and prognosis in lung cancer (LC), but the results are still inconclusive. We systematically evaluated the prognostic value of pretreatment PNI in LC patients by conducting a meta-analysis. METHODS: A comprehensive literature search was performed by retrieving PubMed, EMBASE, and Web of Science, Wan Fang and CNKI databases. We used hazard ratios (HRs) and their 95% confidence intervals (CIs) to assess the associations of PNI with overall survival (OS), disease-free survival/recurrence-free survival (DFS/RFS) and progression-free survival (PFS) in LC patients. RESULTS: A total of 21 studies were enrolled into this meta-analysis, with 17 about no-small cell lung cancer (NSCLC) and 4 about on small-cell lung cancer (SCLC). The results indicated that NSCLCpatients with low PNI had shorter OS (HR: 1.59, 95% CI: 1.28-1.96, P = 0.001), DFS/RFS (HR = 1.74, 95% CI = 1.08-2.80, P = 0.017), and PFS (HR = 1.52, 95% CI = 1.26-1.83, P = 0.002) than patients with high PNI. The robustness of these pooled results were verified by our stratified analysis and sensitivity analysis. Besides, a pooled analysis of 4 studies about SCLC suggested that low PNI was closely associated with worse OS in SCLCpatients as well. CONCLUSION: Low PNI predicts poor survival in LC patients.
Authors: Matteo Ferro; Marina Di Mauro; Sebastiano Cimino; Giuseppe Morgia; Giuseppe Lucarelli; Abdal Rahman Abu Farhan; Mihai Dorin Vartolomei; Angelo Porreca; Francesco Cantiello; Rocco Damiano; Gian Maria Busetto; Francesco Del Giudice; Rodolfo Hurle; Sisto Perdonà; Marco Borghesi; Pierluigi Bove; Riccardo Autorino; Nicolae Crisan; Michele Marchioni; Luigi Schips; Francesco Soria; Andrea Mari; Andrea Minervini; Alessandro Veccia; Michele Battaglia; Daniela Terracciano; Gennaro Musi; Giovanni Cordima; Matteo Muto; Vincenzo Mirone; Ottavio de Cobelli; Giorgio Ivan Russo Journal: Transl Androl Urol Date: 2021-02
Authors: Guohui Xue; Xing Gan; Zhiqiang Wu; Dan Xie; Yan Xiong; Lin Hua; Bing Zhou; Nanjin Zhou; Jie Xiang; Junming Li Journal: Int Immunopharmacol Date: 2020-10-03 Impact factor: 4.932